A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
A multicenter, randomized, double-blind, vehicle controlled phase II clinical study
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF);
• The age requirement for signing the ICF is 18 years old or above, with no gender restrictions;
• During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria;
Locations
Other Locations
China
Chinese Academy of Medical Sciences Hospital of Skin Disease
RECRUITING
Nanjing
Contact Information
Primary
Xiaojuan Lai
lai_xiaojuan@vcarepharmatech.com
15358160458
Time Frame
Start Date: 2025-04-28
Estimated Completion Date: 2025-12-30
Participants
Target number of participants: 114
Treatments
Experimental: VC005 Low Dose groups
VC005 group with Local topical application
Experimental: VC005 high Dose groups
VC005 group with Local topical application
Placebo_comparator: VC005 Placebo groups
VC005 Placebo group with Local topical application
Related Therapeutic Areas
Sponsors
Leads: Jiangsu vcare pharmaceutical technology co., LTD